he company specializes in viral vector technologies to be applied in most sophisticated drug development, i.e. cell and gene therapies, CAR-T. First business occurred in 2007. Since then, the company has received several access fees and milestone payments. Its lentiviral transduction technology, as of May 2019, is being applied in 6 clinical programs. In addition, 3 programs regarding AAV-developments are in a discovery / candidate optimization phase.
Management pursues a 3-pronged approach, geography, technology and preclinical assets. The company is expanding its young Massachusetts operation and is planning for a representation in Japan in 2020. Technology: the company not only aims for increasing yields in its production protocols from discovery to GMP ready, its manufacturing suites are increasingly quality controlled for the company to provide material for tox studies. Given the hundreds of lab and R&D managers the company has been serving over the years, the company operates on a rather sophisticated level of intelligence and networking.
SIRION Biotech enables drug developers to participate in the race for virus based gene therapy and immuno oncolgy medicines. The company specializes in next gen viral vectors for gene therapy and novel vaccine applications. SIRION masters all 3 relevant platforms, adeno- and lentivirus and AAV.
The company holds selected IP in each of the 3 most relevant platforms: the company's unique BAC-technology (Bacterial Artificial Chormosomes) allows SIRION Biotech to build adenovirus from scratch according to specified devel-opment needs. BAC-technology has substantial other advantages over current industry standards in that it generates 100% positive and stable clones and allows for entire expression libraries and novel serotypes. Other IP addresses LentiBOOST™ and LentiTHERAPY, vectors with built in single chain antibodies for much improved T-cell transduction. In the field of AAVs SIRION works from libraries made up of peptide inserts and shuffled capsids for improved cell tropism and gene transfer efficiciencies.